

1646



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: G.A. Demopulos et al. Attorney Docket No.: CH.1.0018.US2  
(OMER118473)

Application No.: 10/031,546 Group Art Unit: 1646

Filed: January 18, 2002 Examiner: P.M. Mertz

Title: SOLUTIONS AND METHODS FOR INHIBITION OF PAIN,  
INFLAMMATION AND CARTILAGE DEGRADATION

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1.  X  Copies of the listed patents and other information are enclosed for the Examiner's use.
2.  X  Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits.
3.  X  The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application.

Respectfully submitted,

CHRISTENSEN O'CONNOR  
JOHNSON KINDNESS<sup>PLLC</sup>

Dennis K. Shelton  
Registration No. 26,997  
Direct Dial No. 206.695.1718

///

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100

I hereby certify that this Third Supplemental Information Disclosure Statement is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date:

1/6/2004

Carol Julian

DKS:cj

LAW OFFICES OF  
CHRISTENSEN O'CONNOR JOHNSON KINDNESS<sup>PLLC</sup>  
1420 Fifth Avenue  
Suite 2800  
Seattle, Washington 98101  
206.682.8100



INFORMATION CITED BY APPLICANTS THAT MAY BE MATERIAL  
TO THE PROSECUTION OF THE SUBJECT APPLICATION

Applicants: Gregory A. Demopoulos et al. Attorney Docket No: CH.1.0018.US2  
(OMER-1-18473)

Serial No: 10/031,546 Group Art Unit: 1646

Filed: January 18, 2002 Examiner: P.M. Mertz

Title: SOLUTIONS AND METHODS FOR INHIBITION OF PAIN, INFLAMMATION  
AND CARTILAGE DEGRADATION

U.S. PATENT DOCUMENTS

*Examiner Initial	ID	Document No.	Date	Name
_____	U222	5,853,746	12/29/1998	Hunziker
_____	U241	5,206,023	04/27/1993	Hunziker
_____	U368	6,093,743	07/25/2000	Lai et al.
_____	U514	6,428,804	08/06/2002	Suzuki et al.
_____	U532	5,811,535	09/22/1998	Adamou et al.
_____	U578	6,004,555	12/21/1999	Thorpe et al.

OMEROS CORPORATION  
1420 Fifth Avenue  
Suite 2600  
Seattle, Washington 98101  
206.623.4688



OTHER INFORMATION  
(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Initial	ID	Document Information
_____	O00855	Goldring, M.B., "Anticytokine therapy for osteoarthritis," <i>Expert Opin. Biol. Ther.</i> , <b>1(5)</b> :817-829 (2001).
_____	O01227	Firestein, G.S., et al., "Anticytokine Therapy in Rheumatoid Arthritis," <i>New Engl. Journal of Med.</i> , <b>337(3)</b> :195-197 (1997).
_____	O01548	Day, C.S., et al., "Myoblast-mediated gene transfer to the joint," <i>J Orthop Res</i> , <b>15(6)</b> :894-903 (1997) (Abstract only).
_____	O01549	Arend, W.P., "The mode of action of cytokine inhibitors," <i>J Rheumatol Suppl.</i> , <b>(65)</b> :16-21 (2002) (Abstract only).
_____	O01560	van de Loo, F.A., et al., "Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators," <i>Rheum Dis Clin North Am</i> , <b>28(1)</b> :127-49 (2002) (Abstract only).
_____	O01561	Maini, R.N., et al., "Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease," <i>Immunol Rev</i> , <b>144</b> :195-223 (1995) (Abstract only).

Examiner	Date Considered
_____	_____

\*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MSK:sj

OMEROS CORPORATION  
1420 Fifth Avenue  
Suite 2600  
Seattle, Washington 98101  
206.623.4688